Daiichi Sankyo is committed to expanding scientific knowledge about edoxaban, as demonstrated through our research program evaluating its use in a broad range of cardiovascular conditions, patient types and clinical settings in atrial fibrillation (AF) and venous thromboembolism (VTE) designed to further build on the results of the pivotal ENGAGE AF and Hokusai-VTE studies.

The goal of EDOSURE is to generate new clinical and real-world-data regarding the use of edoxaban in AF and VTE populations, providing physicians and patients worldwide with greater treatment assurance.

More than 100,000 patients worldwide are expected to participate in the edoxaban clinical research program, EDOSURE, which is comprised of more than 10 randomized, controlled trials, registries and non-interventional studies, including completed, ongoing and future research.

Edoxaban Studies in EDOSURE

Randomized-controlled Clinical Trials in AF and VTE

Nr.

Name

Clinical setting

Comparator

1.

AF patients

VKA

2.

VTE patients

Enoxaparin-Warfarin

3.

AF patients undergoing electrical cardioversion

Enoxaparin-Warfarin

4.

AF patients undergoing PCI

VKA

5.

AF patients undergoing catheter ablation of AF

VKA

6.

AF patients undergoing transcatheter aortic valve implantation (TAVI)

VKA

7.

80 years or older Japanese AF patients who are ineligible for current OAC therapy

placebo

8.

Patients with cancer and an acute VTE event

Subcutaneous Dalteparin

Global and regional registries and non-interventional studies in AF and VTE

Nr.

Name

Clinical setting

1.

Edoxaban treatment in routine clinical practice in AF

2.

Edoxaban treatment in routine clinical practice in VTE

3.

Edoxaban management in diagnostic and therapeutic procedures in AF/VTE

4.

Prevention of thromboembolic events in European Registry in AF patients

5.

All Nippon AF In Elderly Registry in Japan (in more than 75 years in Japan)

6.

Multicentre prospective registry in VTE patients with cancer

AF: atrial fibrillation, OAC: oral anticoagulant, PCI: Percutaneous Coronary Intervention, TAVI: transcatheter aortic valve implantation, VKA: vitamin K antagonist, VTE: venous thromboembolism

Find out more